Diagnosis: Vitiligo

What is Vitiligo?

Pathogenesis

1. Melanocytes with genetic susceptibility are rendered vulnerable by oxidative stress
2. Damaged melanocytes release heat shock proteins (HSP-70, HMGB1) - damage-associated molecular patterns (DAMPs)
3. This activates plasmacytoid dendritic cells and innate lymphoid cells to secrete IFN-alpha and IFN-gamma
4. Keratinocytes produce CXCL9 and CXCL10, recruiting CD4+ helper and CD8+ cytotoxic T cells (CXCR3+)
5. These T cells destroy melanocytes via IFN-gamma and TNF

Clinical Features

• Milky-white depigmented patches with smooth, convex, well-defined margins
• Hairs within the patches may also lose pigment (leukotrichia)
• Lesions tend to appear at sites of trauma (Koebner phenomenon) - hence the knee and lower leg are common sites
• No scaling, induration, or surface change

Classification - Which Type Might This Be?

Key Epidemiology

• Prevalence: 0.5-1% worldwide; up to 8%+ in some regions of India (Andrews' Diseases of the Skin)
• Peak onset: ages 10-30; ~50% of cases begin before age 20
• Associated with other autoimmune conditions (thyroid disease, diabetes, alopecia areata, pernicious anemia)

Management Overview

Important: This assessment is based on visual analysis only and should not replace a formal evaluation by a dermatologist. A Wood's lamp examination and clinical history (duration, progression, family history, associated autoimmune conditions) are needed for a complete workup.

When Phototherapy Fails for Vitiligo

Why Phototherapy May Not Work

• Dorsal hands and feet: respond only ~10-20% of the time
• Mucosal vitiligo (lips), periungual, and acral lesions have essentially no reproducibly effective medical therapy
• Longer disease duration and lower hair follicle density reduce repigmentation potential
• Segmental vitiligo tends to be more phototherapy-resistant

Step-Up Treatment Options

1. Switch or Enhance Phototherapy

2. JAK Inhibitors - The Newest and Most Promising Option

• Topical ruxolitinib cream 1.5% (Opzelura) - FDA-approved (2022) for non-segmental vitiligo. Works by blocking JAK1/JAK2, suppressing the IFN-gamma driven T-cell attack on melanocytes. A 2022 Phase 3 RCT in NEJM showed significant facial repigmentation vs placebo.
• Oral baricitinib (JAK inhibitor) - A 2025 multicenter RCT found that combining 308 nm excimer laser + oral baricitinib significantly outperformed monotherapy in localized refractory non-segmental vitiligo, with a 14.2% higher repigmentation rate. Combination maintained stable pigmentation at 1-year follow-up with no recurrence.

Key finding: JAK inhibitors + targeted phototherapy (excimer laser) work synergistically - the laser activates melanocyte migration while JAK inhibitors suppress the autoimmune attack.

3. Combination Topical Therapy

• Topical calcineurin inhibitors (tacrolimus 0.1% ointment, pimecrolimus 1% cream) - particularly effective for facial vitiligo; use in combination with NB-UVB enhances facial repigmentation (Andrews' Diseases of the Skin)
• Topical corticosteroids - potent/superpotent for 4-6 months; up to 80% repigmentation on face; only 40% on trunk

4. Systemic Immunosuppression (for Rapidly Progressing Disease)

• Oral mini-pulse steroids (betamethasone or dexamethasone 2.5-5 mg on 2 consecutive days/week) - used to arrest active, spreading vitiligo, then transition back to phototherapy
• Long-term systemic immunosuppressives are NOT recommended due to toxicity

5. Surgical Options (for Stable, Treatment-Resistant Disease)

Surgery is especially effective for segmental vitiligo, which is often phototherapy-resistant but responds well surgically. Reserved for <2-3% BSA of exposed skin (Andrews' Diseases of the Skin, p. 1003).

6. Cosmetic Camouflage

• Dihydroxyacetone (DHA) self-tanning creams - stains skin for 5-10 days; works well for lower Fitzpatrick phototypes
• Professional medical camouflage makeup
• Strict sun protection (SPF 50+) to prevent burns in depigmented areas

Decision Framework

Phototherapy failing?
        |
  Is disease active/spreading? --> YES --> Oral mini-pulse steroids to arrest, then retry
        |
        NO
        |
  Is it localized (<10-20% BSA)?
        |
  YES --> Try 308 nm excimer laser + topical ruxolitinib OR topical tacrolimus
        |
  Resistant after 6 months?
        |
  YES --> Surgical option (if stable for 1 year, no Koebner)
        |
  Widespread (>20% BSA)? --> Oral JAK inhibitor (baricitinib/ruxolitinib) + excimer

Important: Please discuss these options with a dermatologist. The best choice depends on the extent of disease, whether it is active or stable, the specific body sites involved, and patient preferences. JAK inhibitors in particular require prescription and monitoring.